Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
Pharmaceutical Care Management Association

2. Address

Address1
325 7th Street NW, 9th Floor
 Address2
​
City
WASHINGTON
 State
DC
 Zip Code
20004
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Ms.
​BRENDA PALMER
​2027565725
​bpalmer@pcmanet.org
5. Senate ID#
​31348-12
7. Client Name Self Check if client is a state or local government or instrumentality
​Pharmaceutical Care Management Association
6. House ID#
​340040000
TYPE OF REPORT 8. Year
​2019
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​1,492,460.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Brenda Palmer
 Date
4/18/2019 3:30:14 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to prescription drug coverage and pharmacy benefits.

Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits.

Issues included in the Administrations drug pricing Blueprint.

Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses

H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act.
H.R.1034/S.640: Phair Pricing Act of 2019.
H.R.1035: Prescription Drug Price Transparency Act.
S. 476: C-THRU Act
S.801/H.R. 1264: Payment Commission Data Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Medicare Payment Advisory Commission (MedPAC), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Federal Trade Commission (FTC), U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Kristin
Bass
​
​
Jonathan
Heafitz
​
​
Katherine
Murphy
​
​
Catherine
Meier
​
​
JC
Scott
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Issues related to prescription drug coverage and pharmacy benefits.

Issues included in the Administrations drug pricing Blueprint.

Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.

Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses.

Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market.

Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars.

H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act.
H.R.1034/S.640: Phair Pricing Act of 2019.
H.R.1035: Prescription Drug Price Transparency Act.
S. 476: C-THRU Act
S.801/H.R. 1264: Payment Commission Data Act
S. 64: Preserve Access to Affordable Generics and Biosimilars Act
H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act
S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act
H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act
S 659: Biologic Patent Transparency Act
H.R.1499: Protecting Consumer Access to Generic Drugs Act
H.R.1520: Purple Book Continuity Act
H.R. 1503: Orange Book Transparency Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Medicare Payment Advisory Commission (MedPAC), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP), Food & Drug Administration (FDA), Federal Trade Commission (FTC)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Kristin
Bass
​
​
Jonathan
Heafitz
​
​
Katherine
Murphy
​
​
Catherine
Meier
​
​
JC
Scott
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues


Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks.

Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy.

Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.

Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses.

H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act.
H.R.1034/S.640: Phair Pricing Act of 2019.
H.R.1035: Prescription Drug Price Transparency Act.
S. 476: C-THRU Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP), Food & Drug Administration (FDA), Federal Trade Commission (FTC), Medicare Payment Advisory Commission (MedPAC)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Kristin
Bass
​
​
Jonathan
Heafitz
​
​
Katherine
Murphy
​
​
Catherine
Meier
​
​
JC
Scott
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)